{"title": "Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice", "doi": "10.1101/2020.03.18.20038018", "citation_id": "2020.03.18.20038018v1", "date": "2020-03-20", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.18.20038018", "abstract": "<p>Background We aim to investigate the profile of acute antibody response in COVID-19 patients, and provide proposals for the usage of antibody test in clinical practice.\nMethods A multi-center cross-section study (285 patients) and a single-center follow-up study (63 patients) were performed to investigate the feature of acute antibody response to SARS-CoV-2. A cohort of 52 COVID-19 suspects and 64 close contacts were enrolled to evaluate the potentiality of the antibody test. \nResults The positive rate for IgG reached 100% around 20 days after symptoms onset. The median day of serocon-version for both lgG and IgM was 13 days after symptoms onset. Seroconversion of IgM occurred at the same time, or earlier, or later than that of IgG. IgG levels in 100% patients (19/19) entered a platform within 6 days after seroconversion. The criteria of IgG seroconversion and \u2265 4-fold increase in the IgG titers in sequential samples together diagnosed 82.9% (34/41) of the patients. Antibody test aided to confirm 4 patients with COVID-19 from 52 suspects who failed to be confirmed by RT-PCR and 7 patients from 148 close contacts with negative RT-PCR.\nConclusion IgM and IgG should be detected simultaneously at the early phase of infection. The serological diagnosis criterion of seroconversion or  \u2265 4-fold increase in the IgG titer is suitable for a majority of COVID-19 patients. Serologic test is helpful for the diagnosis of SARS-CoV-2 infection in suspects and close contacts.</p>", "twitter_description": "Background We aim to investigate the profile of acute antibody response in COVID-19 patients, and provide proposals for the usage of antibody test in clinical practice. Methods A multi-center cross-section study (285 patients) and a single-center follow-up study (63 patients) were performed to investigate the feature of acute antibody response to SARS-CoV-2. A cohort of 52 COVID-19 suspects and 64 close contacts were enrolled to evaluate the potentiality of the antibody test. Results The positive rate for IgG reached 100% around 20 days after symptoms onset. The median day of serocon-version for both lgG and IgM was 13 days after symptoms onset. Seroconversion of IgM occurred at the same time, or earlier, or later than that of IgG. IgG levels in 100% patients (19/19) entered a platform within 6 days after seroconversion. The criteria of IgG seroconversion and \u2265 4-fold increase in the IgG titers in sequential samples together diagnosed 82.9% (34/41) of the patients. Antibody test aided to confirm 4 patients with COVID-19 from 52 suspects who failed to be confirmed by RT-PCR and 7 patients from 148 close contacts with negative RT-PCR. Conclusion IgM and IgG should be detected simultaneously at the early phase of infection. The serological diagnosis criterion of seroconversion or \u2265 4-fold increase in the IgG titer is suitable for a majority of COVID-19 patients. Serologic test is helpful for the diagnosis of SARS-CoV-2 infection in suspects and close contacts.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nThis work was supported by the Emergency Project from the Science & Technology Commission of Chongqing; The Major National S&T program grant (2017ZX10202203 and 2017ZX10302201) from Science & Technology Commission of China; The grant (81871635, 81671997 and 81902060) from the National Natural Science Foundation of China, and the grant (20180141 and 20170413) from the Science & Technology Commission of Yuzhong district, Chongqing.\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nData referred to in the manuscript are available.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.18.20038018v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.18.20038018v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.18.20038018v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/20/2020.03.18.20038018.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.18.20038018v1", "access_rights": "restricted", "authors": ["Quan-xin Long", "Hai-jun Deng", "Juan Chen", "Jieli Hu", "Bei-zhong Liu", "Pu Liao", "Yong Lin", "Li-hua Yu", "Zhan Mo", "Yin-yin Xu", "Fang Gong", "Gui-cheng Wu", "Xian-xiang Zhang", "Yao-kai Chen", "Zhi-jie Li", "Kun Wang", "Xiao-li Zhang", "Wen-guang Tian", "Chang-chun Niu", "Qing-jun Yang", "Jiang-lin Xiang", "Hong-xin Du", "Hua-wen Liu", "Chunhui Lang", "Xiao-he Luo", "Shao-bo Wu", "Xiao-ping Cui", "Zheng Zhou", "Jing Wang", "Cheng-jun Xue", "Xiao-feng Li", "Li Wang", "Xiao-jun Tang", "Yong Zhang", "Jing-fu Qiu", "Xia-mao Liu", "Jin-jing Li", "De-chun Zhang", "Fan Zhang", "Xue-fei Cai", "Deqiang Wang", "Yuan Hu", "Ji-hua Ren", "Ni Tang", "Ping Liu", "Qin Li", "Ai-long Huang"]}